| HOME >> MEDICINE >> TECHNOLOGY |
Diversification strategy at heart of Wyeth M&A 11
Outlook - will Pfizer return to the M&A trail before 2015? 16
SWOT analysis 19
Table of Contents 20
Table of figures 22
Chapter 3 Quarterly news update 23
Latest quarterly sales 23
Latest comment 24
Hope for an Alzheimer's breakthrough remains despite Dimebon's failure 24
Pfizer's novel NGF pain drug is potential game changer 25
Pfizer: Lyrica sNDA withdrawal no cause for anxiety 26
Latest prescription pharma product news 27
Q4 2009 29
Q3 2009 32
Q1 2009 33
Latest corporate news 35
Q1 2010 35
Q4 2009 35
Q3 2009 36
Q2 2009 36
Q1 2009 37
Future product milestones 39
Chapter 4 Company introduction 41
Key findings 41
Background 42
Key corporate developments 42
M&A history 42
Warner-Lambert acquisition 43
Pharmacia acquisition 43
Chapter 5 Company sales 46
Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2003-15 47
Product analysis 49
Product analysis, 2003-09 50
Product analysis, 2009-15 53
Therapy area analysis 56
Geographic analysis 59
Launch/core/expiry analysis 60
Explanation of launch/core/expiry analysis 60
Launch analysis, 2009-15 61
Core analysis, 2009-15 63
Expiry analysis, 2009-15 64
Launch/core/expiry configuration, 2009-15 66
Molecule type analysis 69
Externalization analysis 71
Chapter 6 Company financials 73
Key findings 73
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 74
Operating costs and profit analysis 75
Operating costs and profit analysis, 2002-08 76
Operating cost ratio and profit margin analysis, 200
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |